Technology for Accurate Care
About KAPS Biotech
KAPS Biotech is focused on the development of new cancer biomarkers. The purpose is to create and bring to market new cancer biomarkers that will improve the early detection, treatment and survival of cancer patients.
The current technology was developed by to two researchers who have dedicated their careers to improving cancer outcomes: Drs. Kailash Chadha and Willie Underwood. Over the last 7 years, the pair has combined their unique talents to develop, publish and to bring to market a unique panel of biomarker(s) for the early detection of PCa that can inform PCa treatment decision making and improve monitoring men with PCa.
Dr. Kailash Chadha
Dr. Chadha, a basic scientist, is an expert in the field of cytokine biology. He helped to develop and advance the clinical applications of interferons, identification of novel cancer biomarkers and improve the understanding of the physiological role of Prostatic Specific Antigen (PSA) in prostate cancer (PCa) biology.
Dr. Willie Underwood
Dr. Underwood, a clinician scientist, is an expert in health services research. His research has contributed significantly to improved understanding of racial/ethnic differences in PCa diagnosis, treatment and survival and he has worked to reduced barriers to healthcare.